Physician profile
Infanta Stephen
NPI 1114019072
$3,758.77
in general payments reported to CMS, 2019-2025
25 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2021: $912 · 2022: $204 · 2023: $273 · 2024: $606 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.49 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Abbvie INC. | $650.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $466.86 | 2023-2025 | |
| Lilly USA, LLC | $232.18 | 2023-2025 | Kisunla, Amyvid |
| Biogen, INC. | $221.53 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Amneal Pharmaceuticals LLC | $177.39 | 2023-2025 | Rytary, Crexont |
| Sk Life Science, INC. | $148.75 | 2022-2025 | |
| Argenx US, INC. | $138.70 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Genentech USA, INC. | $122.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $89.50 | 2023-2025 | Austedo Xr |
| Eisai INC. | $87.93 | 2024-2025 | |
| Mdd US Operations, LLC | $66.36 | 2024-2025 | Apokyn |
| Pfizer INC. | $58.61 | 2023-2025 | |
| Boston Scientific Corporation | $52.94 | 2025 | General - Dbs |
| Grifols USA, LLC | $44.55 | 2025 | Gamunex-C |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $44.30 | 2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $40.48 | 2025 | Rexulti |
| Abbott Laboratories | $36.49 | 2024 | Infinity |
| Neurocrine Biosciences, INC. | $33.67 | 2025 | |
| Ucb, INC. | $32.27 | 2024-2025 | Rystiggo, Briviact |
| Emd Serono, INC. | $32.16 | 2023-2025 | Mavenclad |
| Ge Healthcare | $24.08 | 2025 | |
| Neurelis, INC. | $20.10 | 2025 | Valtoco |
| Celgene Corporation | $18.98 | 2025 | Zeposia |
| C2n Diagnostics, LLC | $17.89 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Infanta Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.